The global hormone replacement therapy market was valued at USD 35.05 billion in 2023 and is projected to hit around USD 60.23 billion by 2032, at a CAGR of 6.20% from 2023 to 2032.
Key Points:
- The North America region was valued at USD 11.2 billion in 2022
- Asia Pacific region is expected to grow at a CAGR of 13% from 2023 to 2032
- By product, U.S. hormone replacement therapy market was valued at USD 9 billion in 2022
- In 2022, the menopause indication segment accounted largest revenue share 49%.
- In 2022, the growth hormone deficiency segment accounted market share 23%
- Human growth hormone replacement therapy is expected to grow at a CAGR of 13% from 2023 to 2032.
- The parental route of administration segment accounted market share of around 42% in the 2022.
The prime drivers of hormone replacement therapy are extended interest from regenerative solutions, for instance, against developing and conceptive cycle supporting therapy like menopausal hormonereplacement. Rising revenue in other helpful areas, for instance, growth hormone therapy and thyroid hormone therapy due to almost safe profile, capability, and cost suitability of these prescriptions should influence market improvement.
Get the Free Sample Copy of Report@ https://www.precedenceresearch.com/sample/1852
Additionally, new definitions, for instance, transdermal drugs, gels and creams that recommendation benefits, for instance, straightforwardness of prescription association and impact at region should fabricate the advancement of hormone replacement therapy market during the gauge time span.
Regional Snapshot
North America managed the general market for hormone replacement therapy to the extent that pay share in 2021. Works out like progression the medicine movement structures, improvement of new subtleties, and rising objective people inside North America should stay aware of its solidarity over the gauge period. The NIH communicates that piece of the postmenopausal women have used HRT something like once.
Asia Pacific, on the other hand, should notice the speediest improvement over the check period from 2022 to 2030. Extending care levels and rising point of convergence of clinical benefits providers on the annihilation of hormonal needs should help the advancement of the market inside the region.
Report Highlights
- Estrogen replacement therapy is used in women during post-menopause or hysterectomy and helps them with staying aware of the hormonal balance. Estrogen-based things have been pondered to make the greatest number of arrangements likewise making it the greatest piece.
- The parenteral piece governed the general market to the extent that pay share in 2020. The oral course of association is generally enjoyed for testosterone drugs. The other piece is complete of things like vaginal creams, embeds, vaginal rings, and vaginal tablets.
- In the sort of disease part, menopause should be the speediest creating area over the measure period from 2022 to 2030. According to the estimations given by the American Congress of Obstetricians and Gynecologists, around 6,000 women show up at menopause consistently.
- In the sort of sickness part, menopause should be the fastest creating area over the measure period from 2022 to 2030. According to the estimations given by the American Congress of Obstetricians and Gynecologists, around 6,000 women show up at menopause consistently.
Hormone Replacement Therapy Market Scope
| Report Coverage | Details |
| Market Size by 2032 | USD 60.23 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 6.20% |
| North America Market Share in 2022 | 41% |
| Menopause Indication Segment Market Share in 2022 | 49% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Product, Route of Administration, Indication, Distribution Channel, Geography |
Hormone Replacement Therapy Market Dynamics
Drivers
The essential issue that contributes toward the improvement of the overall hormone replacement therapy market recall climb for regularity of menopausal issue and extension in care about post-menopausal issues among women. Besides, new farewells of hormone replacement therapy should prominently contribute toward the hormone replacement therapy market improvement. Regardless, negative effects of hormone replacement therapy and huge cost of therapy are supposed to hamper the market advancement during the check time span.
Restraints
As indicated by the U.S Women’s Health Initiative, the utilization of blend hormone supplanting therapy accompanies the gamble of advancement of a few tumors including ovarian disease and uterus malignant growths. This viewpoint is supposed to keep the development in reception of hormone replacement therapy in the impending years. Other hormone replacement therapy related problems, for example, stroke, heart issues and blood clumps are additionally expected to adversely affect the development of the hormone replacement therapy market.
Opportunities
The new item improvement as an essential methodology is embraced by the main organizations to upscale their market presence among buyers. These methodologies have brought about the development of hormone replacement therapy market.
Challenges
The affordability has consistently stayed a significant challenge for any drug medication or plan. Besides, lacking medical services repayments have brought about people deciding on less expensive medications with hazy medication adequacy. This provoked fabricates of hormone replacement therapy medications to deliver nonexclusive variants of the details in a bid to overcome any issues between buying force of individuals and hormone replacement therapy drug evaluating.
Read Also: Neurostimulation Devices Market Size to Reach USD 23.9 Bn by 2030
Key Market Developments
- Pfizer Inc. in 2022 finished the obtaining of Arena Pharmaceuticals. This obtaining will prompt upgrade in portfolio to dermatology, cardiology, gastroenterology and so forth.
- Allergen Plc was procured by AbbVie in 2020. This obtaining is probably going to grow the portfolio to oncology, immunology, neuroscience and so forth.
- Teva drugs has presented conventional form of Estrace cream and estradiol vaginal cream in 2018.
- In December 2020, the US FDA supported the Myovant Sciences’ Orgovyx (relugolix), which is an orally regulated therapy that works by hindering the pituitary organ from making hormones called luteinizing hormone and follicle-invigorating hormone, consequently prompting the decrease in how much testosterone created by the gonads. This guides in the therapy of grown-up patients with cutting edge prostate disease.
Hormone Replacement Therapy Market Companies
- Novo Nordisk A/S
- Pfizer Inc.
- Endo International Plc
- Allergen Plc
- Janssen NV
- Novartis AG
- Bayer AG
- Merck KGaA
- Mithra Pharmaceuticals
- Teva Pharmaceuticals
- Mylan N.V
- Other Market Players
Segments Covered in the Report
By Product
- Oestrogen Hormone Replacement Therapy
- Human Growth Hormone Replacement Therapy
- Thyroid Hormone Replacement Therapy
- Testosterone Hormone Replacement Therapy
By Route of Administration
- Oral
- Parenteral
- Transdermal
- Others
By Indication
- Menopause
- Hypothyroidism
- Male Hypogonadism
- Growth Hormone Deficiency
- Others
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies & Stores
- Online Pharmacies
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/